Finn Sawyer Access to Cancer Testing Act

Finn Sawyer Access to Cancer Testing Act

This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer.

Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.

Bill 118 HR 1780, also known as the Finn Sawyer Access to Cancer Testing Act, aims to improve access to cancer testing for individuals in the United States. The bill was introduced by Representative Finn Sawyer and has garnered bipartisan support in Congress.

The key provisions of the bill include increasing funding for cancer testing programs, expanding access to genetic testing for individuals at high risk of developing cancer, and promoting research on new and innovative cancer testing technologies. The bill also seeks to improve coordination between healthcare providers and researchers to ensure that individuals receive timely and accurate cancer testing.

One of the main goals of the Finn Sawyer Access to Cancer Testing Act is to reduce barriers to cancer testing, particularly for underserved communities and individuals with limited access to healthcare. By increasing funding and promoting research in this area, the bill aims to improve early detection and treatment of cancer, ultimately saving lives and reducing healthcare costs. Overall, the Finn Sawyer Access to Cancer Testing Act is a comprehensive piece of legislation that seeks to address the challenges faced by individuals seeking cancer testing in the United States. With its focus on increasing access, funding, and research in this critical area, the bill has the potential to make a significant impact on the fight against cancer.